RCC & penile cancer at ASCO GU: KN-564, NeoAvAx & PERICLES

Jen-Jane Liu, MD, Oregon Health and Science University, Portland, OR, provides an overview of renal cell carcinoma (RCC) and penile cancer updates from the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA. These include updates from the KEYNOTE-564 study (NCT03142334) with updated 30-month follow-up results as well as the anticipated NeoAvAx trial (NCT03341845) evaluating avelumab/axitinib in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.